Compare Ginkgo Bioworks Holdings Inc (DNA) vs Rockwell Automation (ROK) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.

DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.

Rockwell Automation (ROK) trades at $451.86, up 3.82% over 24 hours, with a neutral technical signal. The stock exhibits strong fundamentals, including a 49.09% gross margin and consistent earnings beats, with Q2 2026 EPS of $3.49 surpassing the $3.38 estimate. Recent news highlights AI integration in quality management systems, signaling innovation momentum. Valuation ratios are elevated, with a P/E of 41.85 and P/S of 5.6, reflecting premium pricing.

The outlook remains positive due to robust earnings performance and raised fiscal 2026 guidance, though high valuation multiples and inflation pressures pose risks. Analyst consensus is a Buy with a $507 price target, suggesting 12% upside. Key risks include cost inflation and competitive threats in industrial automation.